CONTEXT: Adipose tissue-derived adipokines may contribute to insulin resistance. OBJECTIVE: We tested the hypothesis that adipokines are associated with insulin resistance in a community-based cohort and that associations are maintained in people with and without the metabolic syndrome (high vs. low risk of diabetes). DESIGN, SETTING, AND PARTICIPANTS: We studied a cross-sectional sample of 2356 individuals attending the seventh examination (1998-2001) of the Framingham Offspring Study. We measured levels of glucose, insulin, adiponectin, resistin, and TNFalpha in fasting blood samples and defined metabolic syndrome by updated National Cholesterol Education Program criteria. We used ANOVA to test associations of adipokines with insulin resistance and multivariable logistic regression models to assess joint associations of adipokines and metabolic syndrome with insulin resistance. MAIN OUTCOME MEASURE: Homeostasis model (HOMA-IR), with insulin resistance defined by HOMA-IR greater than the 75th percentile, was measured. RESULTS: Age- and sex-adjusted HOMA-IR levels were inversely related to adiponectin (r = -0.40, P < 0.0001) and positively related to resistin (r = 0.13, P < 0.0001) and TNFalpha (r = 0.12, P < 0.0001). The prevalence of insulin resistance increased with decreasing tertiles of adiponectin (from 10.9% in the third to 42.5% in the first tertile; P < 0.0001) and increasing tertiles of resistin (from 19.3 to 30.9%; P < 0.0001) and TNFalpha (from 18.8 to 32.0%; P < 0.0001). Results were similar after adjustment for body mass index. These associations were present in individuals with or without the metabolic syndrome. In multivariable regression models, metabolic syndrome and adipokines individually and jointly were significantly associated with insulin resistance. CONCLUSION: Adverse levels of adipokines are associated with insulin resistance in individuals at low or high diabetes risk.
CONTEXT: Adipose tissue-derived adipokines may contribute to insulin resistance. OBJECTIVE: We tested the hypothesis that adipokines are associated with insulin resistance in a community-based cohort and that associations are maintained in people with and without the metabolic syndrome (high vs. low risk of diabetes). DESIGN, SETTING, AND PARTICIPANTS: We studied a cross-sectional sample of 2356 individuals attending the seventh examination (1998-2001) of the Framingham Offspring Study. We measured levels of glucose, insulin, adiponectin, resistin, and TNFalpha in fasting blood samples and defined metabolic syndrome by updated National Cholesterol Education Program criteria. We used ANOVA to test associations of adipokines with insulin resistance and multivariable logistic regression models to assess joint associations of adipokines and metabolic syndrome with insulin resistance. MAIN OUTCOME MEASURE: Homeostasis model (HOMA-IR), with insulin resistance defined by HOMA-IR greater than the 75th percentile, was measured. RESULTS: Age- and sex-adjusted HOMA-IR levels were inversely related to adiponectin (r = -0.40, P < 0.0001) and positively related to resistin (r = 0.13, P < 0.0001) and TNFalpha (r = 0.12, P < 0.0001). The prevalence of insulin resistance increased with decreasing tertiles of adiponectin (from 10.9% in the third to 42.5% in the first tertile; P < 0.0001) and increasing tertiles of resistin (from 19.3 to 30.9%; P < 0.0001) and TNFalpha (from 18.8 to 32.0%; P < 0.0001). Results were similar after adjustment for body mass index. These associations were present in individuals with or without the metabolic syndrome. In multivariable regression models, metabolic syndrome and adipokines individually and jointly were significantly associated with insulin resistance. CONCLUSION: Adverse levels of adipokines are associated with insulin resistance in individuals at low or high diabetes risk.
Authors: J B Meigs; M A Mittleman; D M Nathan; G H Tofler; D E Singer; P M Murphy-Sheehy; I Lipinska; R B D'Agostino; P W Wilson Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: Martin K Rutter; Peter W F Wilson; Lisa M Sullivan; Caroline S Fox; Ralph B D'Agostino; James B Meigs Journal: Circulation Date: 2008-02-04 Impact factor: 29.690
Authors: Josef V Silha; Michal Krsek; Jan V Skrha; Petr Sucharda; B L G Nyomba; Liam J Murphy Journal: Eur J Endocrinol Date: 2003-10 Impact factor: 6.664
Authors: Jennifer H Lee; Jean L Chan; Nikos Yiannakouris; Meropi Kontogianni; Elizabeth Estrada; Richard Seip; Christine Orlova; Christos S Mantzoros Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 5.958
Authors: Otto Tschritter; Andreas Fritsche; Claus Thamer; Michael Haap; Fatemeh Shirkavand; Stefanie Rahe; Harald Staiger; Elke Maerker; Hans Häring; Michael Stumvoll Journal: Diabetes Date: 2003-02 Impact factor: 9.461
Authors: Lisa Patel; Amy C Buckels; Ian J Kinghorn; Paul R Murdock; Joanna D Holbrook; Christopher Plumpton; Colin H Macphee; Stephen A Smith Journal: Biochem Biophys Res Commun Date: 2003-01-10 Impact factor: 3.575
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Bradley F Boeve; Teresa J H Christianson; V Shane Pankratz; Iftikhar J Kullo; Eric G Tangalos; Robert J Ivnik; Ronald C Petersen Journal: Alzheimers Dement Date: 2009-09 Impact factor: 21.566